Abstract:Hepatic fibrosis is an essential pathology of multiple chronicliverdiseases. The aim of this study was to investigate the role of miR-301a-3p in hepatic fibrosis. We found that miR-301a-3p was upregulated in hepatic fibrosis patients and in culture-activated human hepatic stellate cells (HSCs). Interestingly, miR-301a-3p expression was increased in hepatic fibrosis progression mice while decreased in hepatic fibrosis recovery mice, indicating that miR-301a-3p may participate in the hepatic fibrosis pathology. Functionally, the effects of miR-301a-3p both on hepatic fibrosis progression and regression were assessed in vivo. Inhibiting miR-301a-3p amelioratedmouse liver fibrogenesis and collagen deposition and suppressed HSC activation and fibrogenic factor expression. Whereas, in hepatic fibrosis regression, upregulating miR-301a-3p impaired mouse hepatic fibrosis recovery by inducing HSC activation and triggering inflammation. Consistently, gain-of-function and loss-of-function analysis of miR-301a-3p were performed to evaluate its effects on human HSCs LX-2 cell. We found that suppressing miR-301a-3p inhibited LX-2 cell activation and proliferation, and induced LX-2 cell apoptosis, accompaniedby decreased fibrotic mediators expression. Collectively, these findings suggest miR-301a-3p drives liver fibrogenesis and HSC activation in hepatic fibrosis. Mechanistically, we demonstrated miR-301a-3p binds directly to phosphatase and tensin homolog (PTEN) by luciferase reporter analysis, pull-down, and RIP assay. Indicating that miR-301a-3p plays a critical rolein promotingliverfibrogenesis viamodulating the PTEN/platelet derived growth factor β (PDGFR-β) pathway. In conclusion, our findings demonstrate that miR-301a-3p expression is closely correlated with hepatic fibrosis pathology, and that enhancing miR-301a-3p maintains the HSC profibrogenic phenotype, triggers inflammatoryresponses, promotes fibrogenic factor production, and further exacerbates liver fibrogenesis. These findings suggest that miR-301a-3p may serve as a promising diagnostic and prognosis biomarker for hepatic fibrosis treatment.

The Autoregulatory Feedback Loop of Microrna-21/Programmed Cell Death Protein 4/activation Protein-1 (Mir-21/Pdcd4/ap-1) As a Driving Force for Hepatic Fibrosis Development.

Mir-301A-3p Promotes Hepatic Stellate Cells Activation and Liver Fibrogenesis Via Regulating PTEN/PDGFR-β.

MicroRNA-101 Suppresses Liver Fibrosis by Downregulating PI3K/Akt/mTOR Signaling Pathway

Activation of the Mir-34A/sirt1/p53 Signaling Pathway Contributes to the Progress of Liver Fibrosis Via Inducing Apoptosis in Hepatocytes but Not in HSCs.

Microrna-21 Activates Hepatic Stellate Cells Via Pten/Akt Signaling

The Feedback Loop Between Mir-21, PDCD4 and AP-1 Functions As a Driving Force for Renal Fibrogenesis.

MiR-542-3p controls hepatic stellate cell activation and fibrosis via targeting BMP-7.

Mir-345–5P Curbs Hepatic Stellate Cell Activation and Liver Fibrosis Progression by Suppressing Hypoxia-Inducible Factor-1Alpha Expression

MicroRNA-146b Regulates Hepatic Stellate Cell Activation Via Targeting of KLF4.

Mir-20A-5p/tgfbr2 Axis Affects Pro-inflammatory Macrophages and Aggravates Liver Fibrosis.

TGF-β-induced hepatocyte lincRNA-p21 contributes to liver fibrosis in mice

MicroRNA-195-3p promotes hepatic stellate cell activation and liver fibrosis by suppressing PTEN expression

Tgf-Beta-Induced Hepatocyte Lincrna-P21 Contributes To Liver Fibrosis In Mice

MicroRNA-212 activates hepatic stellate cells and promotes liver fibrosis via targeting SMAD7.

Recent perspectives on mechanisms of liver fibrogenesis: microRNA and cell autophagy

Regulatory Effects of Micrornas on Hepatic Stellate Cell Activation and Liver Fibrogenesis

Integration of high‑throughput data of microRNA and mRNA expression profiles reveals novel insights into the mechanism of liver fibrosis.

Inhibition of miR‐188‐5p alleviates hepatic fibrosis by significantly reducing the activation and proliferation of HSCs through PTEN/PI3K/AKT pathway

Research on Promoting Liver Fibrosis Injury by the Targeted Regulation of Mir-202 for HGF to Activate HSC

MicroRNA miR-199a-3p alleviates liver fibrosis by targeting CDK17 in activated hepatic stellate cells

The miR-23b/27b/24-1 Cluster Inhibits Hepatic Fibrosis by Inactivating Hepatic Stellate Cells